X-Ray Therapy

Download PDF

Recent Publications on X-Ray Therapy:
Dose reduction from loss of backscatter in superficial x-ray radiation therapy with the Pantak SXT 150 unit. Loss of backscatter has been measured for a Pantak Therapax SXT 150...	28th June, 2008	Southern Zone Radiation Oncology Service, Mater Centre, Princess Alexandra	Australas Phys Eng Sci Med. 2008 Mar;31(1):49-55.
Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. PURPOSE: Evaluate the rationale for the proposals that prior to a wider...	18th June, 2008	Department of Radiation Oncology, Massachusetts General Hospital and	Radiother Oncol. 2008 Feb;86(2):148-53. Epub 2008 Jan 30. DOI Direct Link
A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. It has been long known that patients treated with ionizing radiation carry...	10th June, 2008	Nuclear Engineering and Engineering Physics, Rensselaer Polytechnic	Phys Med Biol. 2008 Jul 7;53(13):R193-241. Epub 2008 Jun 9. DOI Direct Link
Late adverse effects after soft X-ray therapy of cutaneous malignancies: pruritus, burning, epiphora and insufficient occlusion of the mouth. BACKGROUND: Pruritus, burning, epiphora and insufficient occlusion of the...	22nd May, 2008	Fachklinik Hornheide, Munster, Germany.	J Eur Acad Dermatol Venereol. 2008 May;22(5):555-60. Epub 2007 Dec 7. DOI Direct Link
The Potential Clinical Advantages of Charged Particle Radiotherapy using Protons or Light Ions. The increasing use of charged particle radiotherapy (CPT) in many...	9th May, 2008	Birmingham Cancer Centre, University Hospital Birmingham NHS Trust,	Clin Oncol (R Coll Radiol). 2008 May 5;. DOI Direct Link
→View more research publications.

BioNews Results for X-Ray Therapy:
Asbestos shuts parts of hospital	Morecambe Bay Visitor:  Jun 12 2008 11:43PM Matching: x ray therapy

X-Ray Therapy Clinical Trials:
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma	Lymphoma Interventions: Drug: methotrexate;   Drug: rituximab;   Drug: temozolomide;   Procedure: radiation therapy
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer	Head and Neck Cancer
Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury	Thoracic Neoplasms
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)	Glioblastoma Interventions: Radiation: Radiotherapy;   Drug: Temozolomide
DAHANCA 19: The Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC	Cancer of the Head and Neck
→View more trials.

X-Ray Therapy Patents:
US Patent No.	Title
6509521	X-ray catheter with coaxial conductor
6767531	High dose radionuclide complexes for bone marrow suppression
6811995	Non-invasive enzyme screen for cancer
6841537	Combination therapy using nucleic acids and conventional drugs
6841538	Combination therapy using nucleic acids and radio therapy
→View more patents.

Companies working in the area of X-Ray Therapy from Bioportfolio's Biocorporate database :
Company Name
Gulmay Medical Limited Gulmay Medical Limited commenced operation in 1995 to develop, design, manufacture and market x-ray therapy equipment specifically to the medical market and now has an installed base of superficial... www.gulmaymedical.com/        View full profile
Pariser Dermatology Specialists Pariser Dermatology Specialists began in 1946, when Dr. Harry Pariser moved to Norfolk from Philadelphia. He had grown up in Philadelphia, and had received all his education in the city. After... www.pariserderm.com/        View full profile

BioPortfolio Ltd. offers e-mail and postal lists for X-Ray Therapy scientists - we have details of around 161 individuals working on X-Ray Therapy .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.